

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The impact of quality improvement initiatives to improve CKD referral patterns: A systematic review protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-055456
Article Type:	Protocol
Date Submitted by the Author:	13-Jul-2021
Complete List of Authors:	Ghimire, Anukul; University of Alberta Sultana, Naima; University of Alberta Ye, Feng; University of Alberta Hamonic, Laura; University of Alberta Grill, Allan; University of Toronto, Department of Family and Community Medicine Singer , Alexander; University of Manitoba, Department of Family Medicine Akbari, Ayub; University of Ottawa, Department of Medicine Braam, Branko; University of Alberta Collister, David; University of Manitoba, Department of Medicine; McMaster University, Department of Medicine Jindal, Kailash; University of Alberta Courtney, Mark; University of Alberta Shah, Nikhil; University of Alberta Ronksley, Paul; University of Calgary, Department of Medicine Shurraw, Sabin; University of Alberta Brimble, Kenneth Scott; McMaster University, Department of Medicine Klarenbach, Scott; University of Alberta Chou, Sophia; University of Calgary, Department of Medicine Shojai, Soroush ; University of Alberta Deved, Vinay; University of Alberta Wong, Andrew; Callingwood Medical Center Okpechi, Ikechi; University of Alberta Bello, A; University of Alberta
Keywords:	Chronic renal failure < NEPHROLOGY, Epidemiology < TROPICAL MEDICINE, PRIMARY CARE

SCHOLARONE™
Manuscripts

The impact of quality improvement initiatives to improve CKD referral patterns: A systematic review protocol

Authors:

Anukul Ghimire¹ (anukul@ualberta.ca), Naima Sultana¹ (dr.naimasultana85@gmail.com), Feng Ye¹ (fye@ualberta.ca), Laura Hamonic¹ (lhamonic@ualberta.ca), Alan Grill² (AGrill@msh.on.ca), Alexander Singer³ (alexandersinger@gmail.com), Ayub Akbari⁴ (aakbari@toh.ca), Branko Braam¹ (bbraam@gmail.com), David Collister^{5,6} (drcollister@gmail.com), Kailash Jindal¹ (kjindal@ualberta.ca), Mark Courtney¹ (mc@ualberta.ca), Nikil Shah¹ (nshah1@ualberta.ca), Paul Ronksley⁷ (peronksl@ucalgary.ca), Sabin Shurraw¹ (sshurraw@ualberta.ca), Scott Brimble⁶ (brimbles@gmail.com), Scott Klarenbach¹ (swk@ualberta.ca), Sophia Chou⁷ (Sophia.Chou@albertahealthservices.ca), Soroush Shojai¹ (shojai@ualberta.ca), Vinay Deved¹ (vdeved@telus.net), Andrew Wong⁸ (andrewptwong@hotmail.com), Ikechi Okpechi¹ (iokpechi@ualberta.ca), Aminu K Bello¹ (aminu1@ualberta.ca)

Author affiliations:

- 1: Faculty of Medicine and Dentistry, University of Alberta
- 2: Department of Family and Community Medicine, University of Toronto
- 3: Department of Family Medicine, University of Manitoba
- 4: Department of Medicine, University of Ottawa
- 5: Department of Medicine, University of Manitoba
- 6: Department of Medicine, McMaster University
- 7: Department of Medicine, University of Calgary
- 8: Callingwood Medical Center, Edmonton, Alberta

Corresponding author:

Name: Aminu K. Bello

Postal Address: Division of Nephrology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, T6G 2G3, Canada

Email: aminu1@ualberta.ca **Phone:** 780 492 5737

Abstract word count: 250

Manuscript word count: 2582

Key words: Chronic Renal Failure, Epidemiology, Primary Care

Abstract

Introduction

Chronic kidney disease (CKD) is a global-health problem. A significant proportion of referrals to nephrologists for CKD management are early and guideline-discordant, which may lead to an excess number of referrals and increased wait-times. Various initiatives have been tested to increase the proportion of guideline-concordant referrals and decrease wait times. This paper describes the protocol for a systematic review to study the impacts of quality improvement initiatives aimed at decreasing the number of non-guideline concordant referrals, increasing the number of guideline-concordant referrals, and decreasing wait times for patients to access a nephrologist.

Methods and analysis

We developed this protocol by using the Preferred Reporting Items for Systematic reviews and Meta-Analyses for Protocols (PRISMA-P 2015). We will search empirical electronic databases (e.g. MEDLINE, Embase, Cochrane Library, CINAHL, Web of Science, PsycINFO) and grey literature for studies designed to improve guideline-concordant referrals or to reduce unnecessary referrals of patients with CKD from primary care to nephrology. Our search will include all studies published from database inception to April 2021 with no language restrictions. The studies will be limited to referrals for adult patients to nephrologists. Referrals of CKD patients from non-nephrology specialists (e.g. general internal medicine) will be excluded.

Ethics and dissemination

Ethics approval will not be required, as we will analyze data from studies that have already been published and are publicly accessible. We will share our findings using traditional approaches,

1
2
3 including scientific presentations, open access peer-reviewed platforms, and appropriate
4
5 government and public health agencies.
6
7

8 *PROSPERO* registration
9 # CRD42021247756
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Article Summary

Strengths and limitations of this study

- Our proposed study will focus on improving referral patterns to specialist kidney care which has the potential to increase the proportion of guideline-concordant referrals and decrease wait times for CKD patients.
- Our study findings can be used to form focus groups in the future that will incorporate opinions of patients, policy makers, and scientific researchers to make the objectives of improving CKD referral patterns more meaningful for all stakeholders.
- Our study may reveal which quality improvement (QI) initiatives best improve patient outcomes (e.g. wait times).
- Given that the definition of appropriate referral is usually not uniform across studies, our analysis will be based on different local guidelines, which might affect the interpretation of our results.
- As we anticipate that few articles will report on healthcare costs as part of QI initiatives, we may not be able to report on how changes in healthcare costs impact QI initiatives.

Introduction

Chronic kidney disease (CKD) has become a serious global health concern. In 2017, CKD was reported as the cause of death for approximately 1.2 million people worldwide,¹ and estimates indicate that the number of patients with end-stage kidney disease (ESKD) requiring kidney replacement therapy (KRT) will continue to increase worldwide, reaching 5.4 million by 2030.²

Primary health care (PHC) practitioners play a significant role in managing earlier stages of CKD, when the focus is on addressing the risk factors for CKD progression, such as diabetes, hypertension, and other comorbidities.^{3,4} Estimates from Alberta, Canada indicate that up to 95% of people with CKD are managed in the PHC setting.⁵ Another study reported that 71.9 per 1,000 patients with advanced CKD (stages 3-5) in Canada are also managed in the PHC setting.⁶ CKD management is costly to the healthcare system⁷⁻¹⁰ and cost per person increases as CKD progresses.^{11,12} Thus, effective CKD management at the PHC level has the potential to greatly reduce costs to the health care system, especially given the significantly high costs associated with KRT.¹²⁻¹⁴

Various guidelines and summary papers,^{3,4,15,16} toolkits,¹⁷ and referral pathways¹⁸ are available to help PHC practitioners manage CKD and decide which patients should or should not be referred to nephrologists. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines include specific recommendations for referral to nephrology, including but not limited to eGFR values, urine protein abnormalities, and CKD progression.¹⁶ Despite these internationally recognized recommendations, referral recommendations are not consistent, and vary between different health care systems.^{15,16,19} For example, the Canadian Society of Nephrology recommends

1
2
3 referring CKD patients to nephrology when ACR exceeds 60 mg/mmol whereas KDIGO
4
5 stipulates that referral should be initiated when ACR exceeds 30 mg/mmol.¹⁵
6
7
8
9

10 Timely referrals to nephrology have been shown to be linked to initiation of CKD-specific
11
12 therapies and appropriate initiation of KRT.^{20,21} Although it is well known that late referrals
13
14 increase the risk of mortality, worsen post dialysis outcomes, and are associated with lengthy
15
16 hospital stays and treatment costs,^{22–24} not much is known about the implications of early—
17
18 specifically, non-guideline concordant—referrals. Undoubtedly, non-guideline concordant
19
20 referrals strain the health care system due to an increase in the number of overall referrals and
21
22 prolonged wait times, and thereby delay access to specialty care²⁵ such as nephrology.
23
24
25
26
27

28 It has been shown that approximately 40% of referrals to nephrology for CKD management are
29
30 unnecessary and not concordant with guidelines.^{26,27} There may be various reasons for this. First,
31
32 primary care physicians may not be comfortable with certain aspects of CKD management. For
33
34 example, non-nephrology practices tend to adhere less often to monitoring parathyroid hormone,
35
36 performing follow-up measurements of urine ACR, and various other aspects of CKD care.^{28,29}
37
38 Second, specialty guidelines are continuously being expanded and updated, which places a
39
40 burden on primary care physicians who must become familiar with each one.^{28,30,31} Overall, this
41
42 is an area where quality improvement (QI) initiatives may add substantial value by improving
43
44 provider confidence, patient care, and health efficiency
45
46
47
48
49
50

51 QI analysis is an evolving area in health care with the potential to greatly influence practice
52
53 patterns and reduce quality gaps in various areas of health care. A quality gap is the difference
54
55
56
57
58
59

1
2
3 between health care outcomes and processes in the current state versus what can be achieved by
4 applying professional expertise and implementing QI initiatives.³² With regard to CKD referrals,
5
6 outcome-level gaps include changes in wait times or the total number of referrals, and process-
7
8 level gaps are reflected in how many primary care referrals are found to be guideline-concordant
9
10 versus discordant.
11
12
13

14
15
16
17 QI initiatives are developed to reduce these gaps and inform interventions aimed at improving
18 health outcomes by increasing the rate of effective practices in healthcare. Various taxonomies
19 have been developed to classify QI initiatives into sub-groups based on target focus and delivery
20 method.^{32–36} In a previous systematic review, Faulkner et al. examined interventions in PHC
21 focused on influencing referral rates from primary to secondary care in the United Kingdom.³⁷
22
23 The authors found that most interventions targeting referral rates are professional or
24 organizational in nature, and that organizational interventions tend to reduce referrals to
25 specialist care. Researchers also examined referrals from primary care to specialists in an
26 updated Cochrane systematic review published in 2011, and found that educational activities and
27 the use of structured referral sheets are the only interventions that impact referral rates.³⁸ These
28 methods, however, have not demonstrated the same effectiveness with regard to referrals in the
29 CKD population. A study from Ontario, Canada failed to show a significant change in the
30 proportion of appropriate referrals from primary care after the implementation of a CKD toolkit
31 and educational interventions for PHC providers.¹⁷ Thus, further work is needed to identify
32 which types of interventions have the potential to reduce overall and guideline-discordant
33 referrals, improve wait times to specialist care, and close quality gaps in referral patterns from
34 PHC providers for the CKD population.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 The key objective for this review is to determine the impacts of various QI initiatives on process-
7 based measures of CKD referral patterns from PHC to nephrology, including wait times, number
8 of referrals, and/or proportion of guideline-concordant referrals. This is critically important, as
9
10 PHC plays a prominent role in managing CKD⁶ and our group has collected preliminary data
11
12 indicating that a large proportion of referrals from PHC may be guideline-discordant, thereby
13
14 potentially contributing to increased wait times.
15
16
17
18
19
20

21 **Methods**

22 *Study design*

23
24 We will conduct a systematic review of studies reporting on the impact of QI initiatives aimed at
25
26 ensuring appropriate referral of patients with CKD from PHC to clinical nephrology programs.
27
28 PHC providers are defined as family physicians, family doctors, and general practitioners
29
30 (including nurse practitioners) in the primary care setting; we will exclude general internists and
31
32 pediatricians who may be considered PHC providers in certain geographic regions.³⁸ The
33
34 protocol for this study is based on Preferred Reporting Items for Systematic reviews and Meta-
35
36 Analysis for Protocols 2015 (PRISMA-P-2015).³⁹ We will follow the PRISMA 2020
37
38 methodological guidelines (PRISMA 2020) as we conduct and report the findings of our
39
40 systematic review.⁴⁰ The protocol for this study is registered with PROSPERO
41
42 (CRD42021247756). We have outlined the types of studies to be included based on the nature of
43
44 participants, interventions applied, outcomes reported, and study designs:
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- Types of participants. We will include studies with participants over 18 years of age, regardless of sex, ethnicity, and geographic location who had been diagnosed with CKD but had not initiated KRT when a study intervention was first implemented.
- Types of interventions. We will include any initiative or program designed to ensure guideline-concordant referrals or to reduce unnecessary referrals of patients with CKD from a primary care provider to a nephrology specialist. Various methods have been employed previously, including but not limited to: CKD management/referral pathways, toolkits, electronic referral systems, structured referral forms, and practice facilitation (i.e. consultant-led educational programs for primary care practitioners). We will categorize these studies based on the focus of the intervention, as described in previous studies:^{32,41} (a) provider education; (b) provider reminder systems; (c) audit and feedback; (d) organizational change; (e) financial incentives, regulation, and policy; and (f) other. (Table 1).
- Types of studies. We will include randomized trials, controlled clinical trials, controlled before-after studies, interrupted time series studies, QI reports, and descriptive studies.

Search strategy

We have developed a search strategy in consultation with a research librarian. We will search several electronic databases—i.e. MEDLINE, Embase, Cochrane Library, CINAHL, Web of Science, and PsycINFO—using a combination of controlled vocabulary search terms (i.e. Medical Subject Headings), and the MEDLINE search strategy (Supplementary Table S1). We also will manually search the references of publications meeting our criteria to identify any other work relevant to our review. Furthermore, we will search grey literature (conference abstracts

1
2
3 and proceedings, government and organizational reports, working papers, policy papers) in
4
5 consultation with a librarian.
6
7

8 9 10 *Study outcomes*

11
12 Our outcomes of interest are changes to process-based QI measures: wait times, changes in the
13 total number of referrals, and changes in the proportion of guideline-concordant referrals. We
14 anticipate that included studies will have used various guidelines specific to geographic locations
15 and local practice patterns. For studies that do not specify certain guideline referral criteria, we
16 will document that referral criteria were not used.
17
18
19
20
21
22
23
24

25 26 *Data collection and analysis*

27
28 The PRISMA flow diagram summarizes the recommended study selection process (Figure 1). To
29 screen and select studies to be included, we will use a two-stage collaborative review process. In
30 the first stage, two reviewers (AG and NS) will independently review titles and abstracts of
31 retrieved studies based on the inclusion and exclusion criteria listed in Table 2. In the second
32 stage, full texts of the selected studies will be obtained by these reviewers and analyzed
33 independently to determine eligibility for inclusion in our final review. If necessary, a third
34 reviewer (IO) may be involved to evaluate any discrepancies and advise in cases of
35 disagreement. For any excluded study, we will record at least one reason for exclusion.
36
37
38
39
40
41
42
43
44
45
46
47

48 49 *Data extraction and management*

50
51 Two reviewers will independently retrieve data and enter the summarized details into a data
52 extraction form in Microsoft Excel. Data will include type of study, study design, publication
53 year, first author, location of study and local healthcare system (e.g. private vs. public), CKD
54
55
56
57
58
59
60

1
2
3 stages included in study, assessment of kidney function (eGFR, serum creatinine, and urine
4 albumin levels), referral guidelines/criteria used, a description of the QI intervention utilized,
5
6 duration of intervention and follow up, wait times, and changes in total number of referrals and
7
8 the proportion of guideline-concordant referrals.
9
10
11
12
13

14 *Assessment of risk of bias in included studies*

15
16 We will adapt and utilize the Cochrane Effective Practice and Organization of Care (EPOC) risk
17 of bias criteria⁴² to assess methodological quality and evaluate risk of bias in our retrieved
18
19 studies. The risk of bias per study will be displayed in a risk of bias summary table, and any
20
21 discrepancies will be resolved by a third reviewer.
22
23
24
25
26
27

28 *Data synthesis and analysis*

29
30 We will report changes in wait times, total referrals, and the proportion of guideline-concordant
31 referrals associated with the QI interventions utilized in each study. Changes in the number of
32
33 referrals, the proportion of guideline-concordant referrals, and other outcomes associated with QI
34
35 interventions will be presented as absolute values and reported in the same way across all
36
37 studies. All wait times will be reported as number of days.
38
39
40
41
42
43
44

45 If concerns arise regarding missing or unclear data in the studies analyzed, we will contact the
46 authors to request information related to study methods, referral criteria used, and changes in
47
48 guideline-concordant referrals. Missing outcome data will be summarized in the data extraction
49
50 form and noted in the risk of bias section. Characteristics of included studies will be summarized
51
52 in tables. Intervention effects will be calculated as relative risks (RRs) with 95% CIs for
53
54
55
56
57
58
59
60

1
2
3 dichotomous data, and mean differences (MDs) with 95% CIs for continuous variables. If we
4 identify a sufficient number of studies, and clinical and methodological heterogeneity are
5 reasonable, we will perform a meta-analysis to summarize pooled results using a random effects
6 model.⁴³ Statistical heterogeneity will be quantified using I^2 statistics⁴⁴ in each analysis. If
7 heterogeneity between studies is high ($I^2 > 50\%$), then data will be reported descriptively and we
8 will provide a narrative synthesis of included studies using the Synthesis Without Meta-analysis
9 (SWiM) reporting guideline as a framework.⁴⁵ We will assess publication bias using a
10 regression-based test⁴⁶ and by visually inspecting funnel plots.
11
12
13
14
15
16
17
18
19
20
21
22
23

24 We will conduct a stratified meta-analysis by study characteristics. These include: the use of
25 KDIGO guidelines vs. others, CKD stage at referral, and country income group (low and middle
26 income vs. high income). We will perform categorical comparisons of the different types of QI
27 interventions (i.e., provider education; provider reminder systems; audit and feedback;
28 organizational change; financial incentives, regulation, and policy; and other).³² We will
29 compare the number of QI interventions in each category and the overall impacts of each on wait
30 times, referral numbers, and the proportion of guideline-concordant referrals. This information
31 will be summarized in table format, similar to previous studies that have examined the impacts of
32 QI interventions on referral rates.^{37,38}
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 *Patient and public involvement*

48
49 This protocol for a systematic review will not utilize patient or public involvement. Because no
50 patient data will be collected at this step, this study does not require ethics approval. However,
51 we hope to form focus groups in the future where we will promote patient engagement by
52
53
54
55
56
57
58
59
60

1
2
3 soliciting and incorporating the opinions of CKD patients regarding the relevance and
4 implications of the study protocol and results. We hope to form similar focus groups with PHC
5 providers. We also will involve policy makers at Alberta Health Services who will be interested
6 in analyzing QI measures to enhance local health policies and practices. Furthermore, we will
7 collaborate with scientific researchers at our institutions and others who are interested in this
8 topic and have performed relevant work in this field. These groups will be engaged after the
9 protocol is published and the results of the systematic review have been synthesized.
10
11
12
13
14
15
16
17
18
19
20

21 *Timeline*

22 We will collect data and develop our database from August to December 2021, analyze our data
23 and compile our results from January to June 2022, and engage in knowledge translation activities
24 from July to December 2022 (Figure 2).
25
26
27
28
29
30
31

32 *Ethics and dissemination*

33 Ethics approval will not be needed for our project since we will analyze data from already
34 published studies. Our findings will be shared using traditional approaches, including open
35 access peer-reviewed publication(s), presentations at meetings, and a report.
36
37
38
39
40
41
42
43

44 **Discussion**

45 QI initiatives have significant potential to close quality gaps, improve health systems, and
46 enhance patient outcomes. To the best of our knowledge, no systematic reviews have been
47 performed to examine different QI interventions that have been trialed to ensure appropriate
48 referrals of CKD patients from PHC to nephrology. Our analysis will yield a summary of which
49 types of QI interventions improve referral patterns. These results can guide the strategic
50
51
52
53
54
55
56
57
58
59
60

1
2
3 implementation of future QI initiatives to improve referral patterns and may ultimately enhance
4 knowledge and CKD management practices in primary care settings, improve referral and triage
5 systems, and increase the proportion of guideline-concordant referrals of CKD patients. These
6 implications are significant, especially for public health care systems which may be burdened by
7 both the costs of chronic disease management and long wait times for patients to access
8 specialist care.
9

19 **Data statement**

20 We will make data available upon reasonable request.
21
22
23
24
25
26

27 **Funding statement**

28 This work is supported by a Canadian Institutes of Health Research (CIHR) Project Scheme
29 Grant and AMGEN Canada Incorporated Clinical Innovation Grant awarded to AB. The funders
30 played no role in preparing the protocol content or in drafting the manuscript.
31
32
33
34
35
36
37
38
39
40

41 **Competing interest statement**

42 None
43
44
45
46
47
48
49

50 **Author contributions**

51 AG, NS, FY, IO, and AB developed the concept and drafted the manuscript. FY produced
52 figures for manuscript. NS registered the study with PROSPERO. All authors were involved in
53
54
55
56
57
58
59

1
2
3 developing the protocol methods and revising the manuscript. All authors approved the final
4
5 version to be published.
6
7
8
9

10 **Acknowledgements**

11
12 The authors thank Ms. Sophanny Tiv for her assistance in producing figures for the manuscript.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

References

1. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2020;395(10225):709-733. doi:10.1016/S0140-6736(20)30045-3
2. Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. *Lancet*. 2015;385(9981):1975-1982. doi:10.1016/S0140-6736(14)61601-9
3. Grill AK, Brimble S. Approach to the detection and management of chronic kidney disease: *Can Fam Physician*. 2018;64(10):728-735. <http://www.ncbi.nlm.nih.gov/pubmed/30315015>
<http://www.ncbi.nlm.nih.gov/pubmed/30315015>
4. Vassalotti JA, Centor R, Turner BJ, Greer RC, Choi M, Sequist TD. Practical approach to detection and management of chronic kidney disease for the primary care clinician. *Am J Med*. 2016;129(2):153-162.e7. doi:10.1016/j.amjmed.2015.08.025
5. Alberta Health Services. Kidney Health Strategic Clinical Network 2016–2019 transformational roadmap. Published online 2019. <http://www.albertahealthservices.ca/assets/about/scn/ahs-scn-kh-transformational-roadmap.pdf>
6. Bello AK, Ronksley PE, Tangri N, et al. Prevalence and demographics of CKD in Canadian primary care practices: a cross-sectional study. *Kidney Int Reports*. 2019;4(4):561-570. doi:10.1016/j.ekir.2019.01.005

- 1
2
3 7. Manns B, McKenzie SQ, Au F, Gignac PM, Geller LI. The financial impact of advanced
4 kidney disease on Canada Pension Plan and private disability insurance costs. *Can J*
5 *Kidney Heal Dis*. 2017;4(1):2054358117703986. doi:10.1177/2054358117703986
6
7
8
9
- 10
11 8. Smith DH, Gullion CM, Nichols G, Keith DS, Brown JB. Cost of medical care for chronic
12 kidney disease and comorbidity among enrollees in a large HMO population. *J Am Soc*
13 *Nephrol*. 2004;15(5):1300-1306. doi:10.1097/01.ASN.0000125670.64996.BB
14
15
16
17
- 18
19 9. Wyld MLR, Lee CMY, Zhuo X, et al. Cost to government and society of chronic kidney
20 disease stage 1–5: a national cohort study. *Intern Med J*. 2015;45(7):741-747.
21
22 doi:10.1111/imj.12797
23
24
25
- 26
27 10. Manns B, Hemmelgarn B, Tonelli M, et al. The cost of care for people with chronic
28 kidney disease. *Can J Kidney Heal Dis*. 2019;4(6):2054358119835521.
29
30 doi:10.1177/2054358119835521
31
32
- 33
34 11. Honeycutt AA, Segel JE, Zhuo X, Hoerger TJ, Imai K, Williams D. Medical costs of
35 CKD in the medicare population. *J Am Soc Nephrol*. 2013;24(9):1478-1483.
36
37 doi:10.1681/ASN.2012040392
38
39
40
- 41
42 12. Golestaneh L, Alvarez PJ, Reaven NL, et al. All-cause costs increase exponentially with
43 increased chronic kidney disease stage. *Am J Manag Care*. 2017;23(10 Suppl):S163-S172.
44
45
- 46
47 13. Manns BJ, Mendelssohn DC, Taub KJ. The economics of end-stage renal disease care in
48 Canada: incentives and impact on delivery of care. *Int J Health Care Finance Econ*.
49
50 2007;7(2-3):149-169. doi:10.1007/s10754-007-9022-y
51
52
53
- 54
55 14. Lee H, Manns B, Taub K, et al. Cost analysis of ongoing care of patients with end-stage
56
57
58
59
60

- 1
2
3 renal disease: the impact of dialysis modality and dialysis access. *Am J Kidney Dis.*
4
5 2002;40(3):611-622. doi:10.1053/ajkd.2002.34924
6
7
8
9 15. Akbari A, Clase CM, Acott P, et al. Canadian Society of Nephrology commentary on the
10
11 KDIGO clinical practice guideline for CKD evaluation and management. *Am J Kidney*
12
13 *Dis.* 2015;65(2):177-205. doi:10.1053/j.ajkd.2014.10.013
14
15
16 16. KDIGO, CKD. KDIGO CPG for evaluation & management of CKD 2013. *Kidney Int*
17
18 *Suppl.* 2013;3(1):1-150.
19
20
21 17. Brimble KS, Boll P, Grill AK, et al. Impact of the KidneyWise toolkit on chronic kidney
22
23 disease referral practices in Ontario primary care: a prospective evaluation. *BMJ Open.*
24
25 2020;10(2):e032838. doi:10.1136/bmjopen-2019-032838
26
27
28 18. CKD pathway. Accessed June 12, 2021. <http://www.ckdpathway.ca/>
29
30
31 19. De Coster C, McLaughlin K, Noseworthy TW. Criteria for referring patients with renal
32
33 disease for nephrology consultation: a review of the literature. *J Nephrol.* 2010;23(4):399-
34
35 407.
36
37
38 20. Hommel K, Madsen M, Kamper AL. The importance of early referral for the treatment of
39
40 chronic kidney disease: a Danish nationwide cohort study. *BMC Nephrol.* 2012;13:108.
41
42 doi:10.1186/1471-2369-13-108
43
44
45 21. Smart NA, Dieberg G, Ladhani M, Titus T. Early referral to specialist nephrology services
46
47 for preventing the progression to end-stage kidney disease. *Cochrane Database Syst Rev.*
48
49 2014;6:CD007333. doi:10.1002/14651858.CD007333.pub2
50
51
52 22. Navaneethan SD, Aloudat S, Singh S. A systematic review of patient and health system
53
54
55
56
57
58
59
60

- characteristics associated with late referral in chronic kidney disease. *BMC Nephrol.* 2008;9:3. doi:10.1186/1471-2369-9-3
23. Stack AG. Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the United States. *Am J Kidney Dis.* 2003;41(2):301-318. doi:10.1053/ajkd.2003.50038
24. Kazmi WH, Obrador GT, Khan SS, Pereira BJJ, Kausz AT. Late nephrology referral and mortality among patients with end-stage renal disease: a propensity score analysis. *Nephrol Dial Transplant.* 2004;19(7):1808-1814. doi:10.1093/ndt/gfg573
25. MacKinnon JC. Wait times in Canada. *Healthc Manag Forum.* 2017;30(4):190-192. doi:10.1177/0840470417700162
26. Wright J, Glenister KM, Thwaites R, Terry D. The importance of adequate referrals for chronic kidney disease. *Aust J Gen Pract.* 2018;47(1-2):58-62. doi:10.31128/AFP-08-17-4302
27. Lane C, Pirabhahar S, Robins J, Tranter S, Brown M, Katz I. Improving nephrology service delivery—accessing the specialist. *Aust Fam Physician.* 2016;45(4):223-228.
28. Bello AK, Ronksley PE, Tangri N, et al. Quality of chronic kidney disease management in Canadian primary care. *JAMA Netw open.* 2019;2(9):e1910704. doi:10.1001/jamanetworkopen.2019.10704
29. Patwardhan MB, Samsa GP, Matchar DB, Haley WE. Advanced chronic kidney disease practice patterns among nephrologists and non-nephrologists: a database analysis. *Clin J Am Soc Nephrol.* 2007;2(2):277-283. doi:10.2215/CJN.02600706

- 1
2
3 30. Østbye T, Yarnall KSH, Krause KM, Pollak KI, Gradison M, Michener JL. Is there time
4 for management of patients with chronic diseases in primary care? *Ann Fam Med*.
5
6 2005;3(3):209-214. doi:10.1370/afm.310
7
8
9
10
11 31. Yarnall KSH, Pollak KI, Østbye T, Krause KM, Michener JL. Primary care: is there
12 enough time for prevention? *Am J Public Health*. 2003;93(4):635-641.
13
14 doi:10.2105/AJPH.93.4.635
15
16
17
18 32. Shojania K, McDonald K, Watcher R, Owens D. *Closing the quality gap: a critical*
19 *analysis of quality improvement strategies. Volume 1: series overview and methodology.*
20 *Technical Review 9*; 2004.
21
22
23
24
25
26 33. Stone EG, Morton SC, Hulscher ME, et al. Interventions that increase use of adult
27 immunization and cancer screening services: A meta-analysis. *Ann Intern Med*.
28
29 2002;136(9):641-651. doi:10.7326/0003-4819-136-9-200205070-00006
30
31
32
33 34. Stafford RS. Alternative strategies for controlling rising cesarean section rates. *JAMA*.
34
35 1990;263(5):683-687. doi:10.1001/jama.1990.03440050077037
36
37
38
39 35. Weingarten SR, Henning JM, Badamgarav E, et al. Interventions used in disease
40 management programmes for patients with chronic illness which ones work? Meta-
41 analysis of published reports. *BMJ*. 2002;325:925. doi:10.1136/bmj.325.7370.925
42
43
44
45
46 36. Grimshaw JM, Shirran L, Thomas R, et al. Changing provider behavior: an overview of
47 systematic reviews of interventions. *Med Care*. 2001;39(8 Suppl 2):II2-45.
48
49
50
51 37. Faulkner A, Mills N, Bainton D, et al. A systematic review of the effect of primary care-
52 based service innovations on quality and patterns of referral to specialist secondary care.
53
54
55
56
57
58
59
60

- 1
2
3 *Br J Gen Pract.* 2003;53:878-884.
4
5 <http://www.ingentaconnect.com/content/rcgp/bjgp/2003/00000053/00000496/art00011%5>
6
7 [Cnhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC1314732/pdf/14702909.pdf](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1314732/pdf/14702909.pdf)
8
9
10
11 38. Akbari A, Mayhew A, Al-Alawi MA, et al. Interventions to improve outpatient referrals
12 from primary care to secondary care. *Cochrane Database Syst Rev.* 2008;4:CD005471.
13 doi:10.1002/14651858.CD005471.pub2
14
15
16
17
18 39. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review
19 and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev.* 2015;4(1):1.
20 doi:10.1186/2046-4053-4-1
21
22
23
24
25
26 40. Page MJ, McKenzie JE, Bossuyt PM, et al. Updating guidance for reporting systematic
27 reviews: development of the PRISMA 2020 statement. *J Clin Epidemiol.* 2021;134:103-
28 112. doi:10.1016/j.jclinepi.2021.02.003
29
30
31
32
33 41. McDonald KM, Chang C, Schultz EJ. *Methods research report. Through the quality*
34 *kaleidoscope: reflections on the science and practice of improving health care quality;*
35 2013. Accessed June 13, 2021. www.EffectiveHealthCare.ahrq.gov/reports/final.cfm.
36
37
38
39
40
41 42. Cochrane Effective Practice and Organisation of Care (EPOC). *Suggested risk of bias*
42 *criteria for EPOC reviews.* 2017;1-4.
43 [https://epoc.cochrane.org/sites/epoc.cochrane.org/files/public/uploads/Resources-for-](https://epoc.cochrane.org/sites/epoc.cochrane.org/files/public/uploads/Resources-for-authors2017/suggested_risk_of_bias_criteria_for_epoc_reviews.pdf)
44 [authors2017/suggested_risk_of_bias_criteria_for_epoc_reviews.pdf](https://epoc.cochrane.org/sites/epoc.cochrane.org/files/public/uploads/Resources-for-authors2017/suggested_risk_of_bias_criteria_for_epoc_reviews.pdf)
45
46
47
48
49
50
51 43. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials.*
52 1986;7(3):177-188. doi:10.1016/0197-2456(86)90046-2
53
54
55
56
57
58
59
60

- 1
2
3 44. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*.
4 2002;21(11):1539-1558. doi:10.1002/sim.1186
5
6
7
8 45. Campbell M, Mckenzie JE, Sowden A, et al. Synthesis without meta-analysis (SWiM) in
9 systematic reviews: reporting guideline. *BMJ*. 2020;368:16890. doi:10.1136/bmj.l6890
10
11
12
13 46. Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ. Publication and related biases.
14 *Health Technol Assess*. 2000;4(10). doi:10.3310/hta4100
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Taxonomy of interventions used in the systematic review

Intervention type	Definition
Provider education	Interventions aimed at training care providers, including educational workshops/meetings, outreach programs, and distribution of educational materials
Provider reminder systems	Providing specific information about clinical encounters with the aim of prompting clinicians to recall information or promote a certain aspect of care
Audit and feedback	Methods that provide a review of clinical performance for health care providers and institutions to help improve quality of a certain aspect of care
Other	Interventions not covered in the previously listed items, e.g. organizational change initiatives, financial incentives, patient reminder systems, patient education, promotion of self-management, and facilitated relay of clinical data to providers

Table 2: Inclusion and exclusion criteria for this study


Inclusion criteria	Exclusion criteria
- Studies involving CKD patients who are not being managed with KRT.	- Studies where referrals are not from PHC to nephrology (e.g. referrals from or to general internal medicine for CKD).
- Studies reporting changes in process-based QI measures (wait times, number of referrals, or changes in guideline-concordant referrals) for CKD patients.	- Review articles, editorials, letters to the editor, commentaries, case studies, case reports, images.
- Studies reporting at least one outcome measure (referral numbers, rate or proportion of guideline concordant referrals, or wait times).	- Studies where we cannot obtain relevant data (e.g. method of intervention or outcomes reported) even after contacting authors.
- No restrictions on publication date.	- Studies where the outcomes of interest (referral numbers, wait times, guideline-concordant referral rate) are not clearly reported.
- No restrictions on language.	
- No restrictions on the referral guidelines (e.g. KDIGO vs. local/national guidelines) used.	

Supplementary Table S1

1. exp Renal Insufficiency, Chronic/
2. Chronic Kidney disease*.mp.
3. chronic kidney insufficienc*.mp.
4. chronic renal disease*.mp.
5. chronic renal insufficienc*.mp.
6. CKD.mp.
7. Renal fail*.mp.
8. Kidney fail*.mp.
9. or/1-8
10. Organizational innovation/
11. clinical audit/ or medical audit/ or nursing audit/
12. Quality Improvement/
13. education/ or education, professional/ or education, continuing/ or education, medical, continuing/ or education, nursing, continuing/ or education, professional, retraining/
14. (Quality* adj2 improv*).mp.
15. ((Provider or doctor* or physician* or nurse* or health personnel* or healthcare personnel*) adj4 (educat* or learn* or "reminder system*")).mp.
16. (Organization* adj3 (change* or restructure* or revamp or reform* or revise* or innovat*)).mp.
17. Audit*.mp.
18. Feedback/
19. feedback.mp.
20. Physician Incentive Plans/
21. (financ* adj2 incentiv*).mp.
22. (incent* adj2 (plan or plans)).mp.
23. social control, formal/ or government regulation/ or mandatory programs/ or social control policies/ or organizational policy/ or public policy/ or health policy/ or health care reform/
24. regulat*.mp.
25. (policy or policies).mp.
26. or/10-25
27. "Referral and Consultation"/ or (referral* or consultation* or consults or consult).mp.
28. 26 and 27
29. (((Improv* or amerlior* or better or enhance* or correct* or increase* or progress or facilitat* or promote* or raise* or augment* or elevate* or appropriate) adj3 (referral* or consultation* or consult or consults)) and (guide* or policy or policies or regulation* or toolkit* or report*)).mp.
30. ((Reduce or reduction* or decrease* or lessen* or minimize* or diminish* or lower* or avoid*) adj3 ((unnecessary or avoidable or superfluous or unneeded or irrelevant or late or traditional) adj2 (referral* or consultation* or consult or consults))).mp.


1
2
3 31. wait* time*.mp. and ((referral* or consultation* or consult or consults).mp. or
4 "Referral and Consultation"/) and (guide* or policy or policies or regulation* or toolkit* or
5 reporting).mp.
6 32. 28 or 29 or 30 or 31
7 33. 9 and 32
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



*other sources (online publications, technical reports, policy briefs, etc.)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47



Reporting checklist for protocol of a systematic review and meta analysis.

Based on the PRISMA-P guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Reporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

		Page
	Reporting Item	Number
Title		
Identification	#1a Identify the report as a protocol of a systematic review	1
Update	#1b If the protocol is for an update of a previous systematic review, identify as such	N/A

Registration

[#2](#) If registered, provide the name of the registry (such as PROSPERO) and registration number 2

Authors

[#3a](#) Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author 1

[#3b](#) Describe contributions of protocol authors and identify the guarantor of the review 14

Amendments

[#4](#) If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments N/A

Support

[#5a](#) Indicate sources of financial or other support for the review 14

[#5b](#) Provide name for the review funder and / or sponsor 14

[#5c](#) Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol 14

Introduction

1	Rationale	#6	Describe the rationale for the review in the context of what is	3-8
2			already known	
3				
4				
5				
6	Objectives	#7	Provide an explicit statement of the question(s) the review	8
7			will address with reference to participants, interventions,	
8			comparators, and outcomes (PICO)	
9				
10				
11				
12				
13				
14	Methods			
15				
16				
17	Eligibility criteria	#8	Specify the study characteristics (such as PICO, study	8-9, 23
18			design, setting, time frame) and report characteristics (such	
19			as years considered, language, publication status) to be	
20			used as criteria for eligibility for the review	
21				
22				
23				
24				
25				
26				
27	Information	#9	Describe all intended information sources (such as	8-9
28			electronic databases, contact with study authors, trial	
29	sources		registers or other grey literature sources) with planned dates	
30			of coverage	
31				
32				
33				
34				
35				
36				
37	Search strategy	#10	Present draft of search strategy to be used for at least one	9-10, 25
38			electronic database, including planned limits, such that it	
39			could be repeated	
40				
41				
42				
43				
44				
45	Study records -	#11a	Describe the mechanism(s) that will be used to manage	10
46	data management		records and data throughout the review	
47				
48				
49				
50	Study records -	#11b	State the process that will be used for selecting studies	10
51	selection process		(such as two independent reviewers) through each phase of	
52			the review (that is, screening, eligibility and inclusion in	
53			meta-analysis)	
54				
55				
56				
57				
58				
59				
60				

1	Study records -	#11c	Describe planned method of extracting data from reports	10
2				
3	data collection		(such as piloting forms, done independently, in duplicate),	
4				
5	process		any processes for obtaining and confirming data from	
6				
7			investigators	
8				
9				
10				
11	Data items	#12	List and define all variables for which data will be sought	9
12				
13			(such as PICO items, funding sources), any pre-planned	
14				
15			data assumptions and simplifications	
16				
17				
18	Outcomes and	#13	List and define all outcomes for which data will be sought,	10
19				
20	prioritization		including prioritization of main and additional outcomes, with	
21				
22			rationale	
23				
24				
25				
26	Risk of bias in	#14	Describe anticipated methods for assessing risk of bias of	11
27				
28	individual studies		individual studies, including whether this will be done at the	
29				
30			outcome or study level, or both; state how this information	
31				
32			will be used in data synthesis	
33				
34				
35				
36	Data synthesis	#15a	Describe criteria under which study data will be	11
37				
38			quantitatively synthesised	
39				
40				
41	Data synthesis	#15b	If data are appropriate for quantitative synthesis, describe	11
42				
43			planned summary measures, methods of handling data and	
44				
45			methods of combining data from studies, including any	
46				
47			planned exploration of consistency (such as I ² , Kendall's τ)	
48				
49				
50				
51	Data synthesis	#15c	Describe any proposed additional analyses (such as	11
52				
53			sensitivity or subgroup analyses, meta-regression)	
54				
55				
56				
57				
58				
59				
60				

1	Data synthesis	#15d	If quantitative synthesis is not appropriate, describe the type	N/A
2			of summary planned	
3				
4				
5				
6	Meta-bias(es)	#16	Specify any planned assessment of meta-bias(es) (such as	11
7			publication bias across studies, selective reporting within	
8			studies)	
9				
10				
11				
12				
13				
14	Confidence in	#17	Describe how the strength of the body of evidence will be	N/A
15	cumulative		assessed (such as GRADE)	
16				
17	evidence			
18				
19				
20				
21				

22 The PRISMA-P elaboration and explanation paper is distributed under the terms of the Creative
 23 Commons Attribution License CC-BY. This checklist was completed on 28. June 2021 using
 24 <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with
 25 [Penelope.ai](#)
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

BMJ Open

The impact of quality improvement initiatives to improve CKD referral patterns: A systematic review protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-055456.R1
Article Type:	Protocol
Date Submitted by the Author:	26-Feb-2022
Complete List of Authors:	Ghimire, Anukul; University of Alberta Sultana, Naima; University of Alberta Ye, Feng; University of Alberta Hamonic, Laura; University of Alberta Grill, Allan; University of Toronto, Department of Family and Community Medicine Singer, Alexander; University of Manitoba, Department of Family Medicine Akbari, Ayub; University of Ottawa, Department of Medicine Braam, Branko; University of Alberta Collister, David; University of Manitoba, Department of Medicine; McMaster University, Department of Medicine Jindal, Kailash; University of Alberta Courtney, Mark; University of Alberta Shah, Nikhil; University of Alberta Ronksley, Paul; University of Calgary, Department of Medicine Shurraw, Sabin; University of Alberta Brimble, Kenneth Scott; McMaster University, Department of Medicine Klarenbach, Scott; University of Alberta Chou, Sophia; University of Calgary, Department of Medicine Shojai, Soroush; University of Alberta Deved, Vinay; University of Alberta Wong, Andrew; Callingwood Medical Center Okpechi, Ikechi; University of Alberta Bello, A; University of Alberta
Primary Subject Heading:	Renal medicine
Secondary Subject Heading:	Epidemiology, Renal medicine, Health services research
Keywords:	Chronic renal failure < NEPHROLOGY, Epidemiology < TROPICAL MEDICINE, PRIMARY CARE

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

**The impact of quality improvement initiatives to improve CKD referral patterns:
A systematic review protocol**

Authors:

Anukul Ghimire¹ (anukul@ualberta.ca), Naima Sultana¹ (dr.naimasultana85@gmail.com), Feng Ye¹ (fye@ualberta.ca), Laura Hamonic¹ (lhamonic@ualberta.ca), Alan Grill² (AGrill@msh.on.ca), Alexander Singer³ (alexandersinger@gmail.com), Ayub Akbari⁴ (aakbari@toh.ca), Branko Braam¹ (bbraam@gmail.com), David Collister^{5,6} (drcollister@gmail.com), Kailash Jindal¹ (kjindal@ualberta.ca), Mark Courtney¹ (mc@ualberta.ca), Nikil Shah¹ (nshah1@ualberta.ca), Paul Ronksley⁷ (peronksl@ucalgary.ca), Sabin Shurraw¹ (sshurraw@ualberta.ca), Scott Brimble⁶ (brimbles@gmail.com), Scott Klarenbach¹ (swk@ualberta.ca), Sophia Chou⁷ (Sophia.Chou@albertahealthservices.ca), Soroush Shojai¹ (shojai@ualberta.ca), Vinay Deved¹ (vdeved@telus.net), Andrew Wong⁸ (andrewptwong@hotmail.com), Ikechi Okpechi¹ (iokpechi@ualberta.ca), Aminu K Bello¹ (aminu1@ualberta.ca)

Author affiliations:

- 1: Faculty of Medicine and Dentistry, University of Alberta
- 2: Department of Family and Community Medicine, University of Toronto
- 3: Department of Family Medicine, University of Manitoba
- 4: Department of Medicine, University of Ottawa
- 5: Department of Medicine, University of Manitoba
- 6: Department of Medicine, McMaster University
- 7: Department of Medicine, University of Calgary
- 8: Callingwood Medical Center, Edmonton, Alberta

Corresponding author:

Name: Aminu K. Bello

Postal Address: Division of Nephrology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, T6G 2G3, Canada

Email: aminu1@ualberta.ca **Phone:** 780 492 5737

Abstract word count: 250

Manuscript word count: 2825

Key words: Chronic Renal Failure, Epidemiology, Primary Care

Abstract

Introduction

Chronic kidney disease (CKD) is a global-health problem. A significant proportion of referrals to nephrologists for CKD management are early and guideline-discordant, which may lead to an excess number of referrals and increased wait-times. Various initiatives have been tested to increase the proportion of guideline-concordant referrals and decrease wait times. This paper describes the protocol for a systematic review to study the impacts of quality improvement initiatives aimed at decreasing the number of non-guideline concordant referrals, increasing the number of guideline-concordant referrals, and decreasing wait times for patients to access a nephrologist.

Methods and analysis

We developed this protocol by using the Preferred Reporting Items for Systematic reviews and Meta-Analyses for Protocols (PRISMA-P 2015). We will search the following empirical electronic databases: MEDLINE, Embase, Cochrane Library, CINAHL, Web of Science, PsycINFO and grey literature for studies designed to improve guideline-concordant referrals or to reduce unnecessary referrals of patients with CKD from primary care to nephrology. Our search will include all studies published from database inception to April 2021 with no language restrictions. The studies will be limited to referrals for adult patients to nephrologists. Referrals of CKD patients from non-nephrology specialists (e.g., general internal medicine) will be excluded.

Ethics and dissemination

1
2
3 Ethics approval will not be required, as we will analyze data from studies that have already been
4
5 published and are publicly accessible. We will share our findings using traditional approaches,
6
7 including scientific presentations, open access peer-reviewed platforms, and appropriate
8
9 government and public health agencies.
10
11
12

13 *PROSPERO registration*
14 # CRD42021247756
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Article Summary

Strengths and limitations of this study

- Our proposed study will focus on improving referral patterns to specialist kidney care which has the potential to increase the proportion of guideline-concordant referrals and decrease wait times for CKD patients.
- Our study findings can inform focus groups in the future that will incorporate opinions of patients, policy makers, and scientific researchers to further explore methods in enhancing referral patterns from primary care to nephrologists.
- Our study may reveal which quality improvement (QI) initiatives best improve patient outcomes (e.g., wait times).
- Given that the definition of appropriate referral is usually not uniform across studies, our analysis will be based on different local guidelines, which might affect the interpretation of our results.

Introduction

Chronic kidney disease (CKD) has become a serious global health concern. In 2017, CKD was reported as the cause of death for approximately 1.2 million people worldwide,¹ and estimates indicate that the number of patients with end-stage kidney disease (ESKD) requiring kidney replacement therapy (KRT) will continue to increase worldwide, reaching 5.4 million by 2030.²

Primary health care (PHC) practitioners play a significant role in managing earlier stages of CKD, when the focus is on addressing the risk factors for CKD progression, such as diabetes, hypertension, and other comorbidities.^{3,4} Estimates from Alberta, Canada indicate that up to 95% of people with CKD are managed in the PHC setting.⁵ Another study reported that 71.9 per 1,000 patients with advanced CKD (stages 3-5) in Canada are also managed in the PHC setting.⁶ CKD management is costly to the healthcare system⁷⁻¹⁰ and cost per person increases as CKD progresses.^{11,12} Thus, effective CKD management at the PHC level has the potential to greatly reduce costs to the health care system, especially given the significantly high costs associated with KRT.¹²⁻¹⁴

Various guidelines and summary papers,^{3,4,15,16} toolkits,¹⁷ and referral pathways¹⁸ are available to help PHC practitioners manage CKD and decide which patients should or should not be referred to nephrologists. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines include specific recommendations for referral to nephrology, including but not limited to eGFR values, urine protein abnormalities, and CKD progression.¹⁶ Despite these internationally recognized recommendations, referral recommendations are not consistent, and vary between different health care systems.^{15,16,19} For example, the Canadian Society of Nephrology recommends

1
2
3 referring CKD patients to nephrology when ACR exceeds 60 mg/mmol whereas KDIGO
4
5 stipulates that referral should be initiated when ACR exceeds 30 mg/mmol.¹⁵
6
7
8
9

10 Timely referrals to nephrology have been shown to be linked to initiation of CKD-specific
11
12 therapies and appropriate initiation of KRT.^{20,21} Although it is well known that late referrals
13
14 increase the risk of mortality, worsen post dialysis outcomes, and are associated with lengthy
15
16 hospital stays and treatment costs,^{22–24} not much is known about the implications of early—
17
18 specifically, non-guideline concordant—referrals. Non-guideline concordant referrals may strain
19
20 the health care system due to an increase in the number of overall referrals and prolonged wait
21
22 times, and thereby delay access to specialty care²⁵ such as nephrology.
23
24
25
26
27

28 It has been shown that approximately 40% of referrals to nephrology for CKD management are
29
30 not concordant with guidelines.^{26,27} There may be various reasons for this. First, primary care
31
32 physicians may not be comfortable with certain aspects of CKD management. For example, non-
33
34 nephrology practices tend to adhere less often to monitoring parathyroid hormone, performing
35
36 follow-up measurements of urine ACR, and various other aspects of CKD care.^{28,29} Second,
37
38 specialty guidelines are continuously being expanded and updated, which places a burden on
39
40 primary care physicians who must become familiar with each one.^{28,30,31} Overall, this is an area
41
42 where quality improvement (QI) initiatives may add substantial value by improving provider
43
44 confidence, patient care, and health efficiency
45
46
47
48
49
50

51 QI is an evolving area in health care with the potential to greatly influence practice patterns and
52
53 reduce quality gaps in various areas of health care. A quality gap is the difference between health
54
55
56
57
58
59

1
2
3 care outcomes and processes in the current state versus what can be achieved by applying
4 professional expertise and implementing QI initiatives.³² With regard to CKD referrals, outcome-
5 level gaps include changes in wait times or the total number of referrals, and process-level gaps
6 are reflected in how many primary care referrals are found to be guideline-concordant versus
7 discordant.
8
9

10
11
12
13
14
15
16
17 QI initiatives are developed to reduce these gaps and inform interventions aimed at improving
18 health outcomes by increasing the rate of effective practices in healthcare. Various taxonomies
19 have been developed to classify QI initiatives into sub-groups based on target focus and delivery
20 method.^{32–36} In a previous systematic review, Faulkner et al. examined interventions in PHC
21 focused on influencing referral rates from primary to secondary care in the United Kingdom.³⁷
22 The authors found that most interventions targeting referral rates are professional (defined as
23 interventions such education for PHC, information provision, or guidelines) or organizational
24 (defined as primary healthcare and specialist provider schemes, general practitioner fundholding
25 schemes, and open access referral schemes) in nature, and that organizational interventions tend
26 to reduce referrals to specialist care. Researchers also examined referrals from primary care to
27 specialists in an updated Cochrane systematic review published in 2011, and found that
28 educational activities and the use of structured referral sheets are the only interventions that
29 impact referral rates.³⁸ These methods, however, have not demonstrated the same effectiveness
30 with regard to referrals in the CKD population. A study from Ontario, Canada failed to show a
31 significant change in the proportion of appropriate referrals from primary care after the
32 implementation of a CKD toolkit and educational interventions for PHC providers.¹⁷ Thus,
33 further work is needed to identify which types of interventions have the potential to reduce
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 overall and guideline-discordant referrals, improve wait times to specialist care, and close quality
4 gaps in referral patterns from PHC providers for the CKD population.
5
6
7
8
9

10 The key objective for this review is to determine the impacts of various QI initiatives on process-
11 based measures of CKD referral patterns from PHC to nephrology, including wait times, number
12 of referrals, and/or proportion of guideline-concordant referrals. This is critically important, as
13 PHC plays a prominent role in managing CKD⁶ and our group has collected preliminary data
14 indicating that a large proportion of referrals from PHC may be guideline-discordant, thereby
15 potentially contributing to increased wait times.
16
17
18
19
20
21
22
23
24
25

26 **Methods**

27 *Study design*

28
29 We will conduct a systematic review of studies reporting on the impact of QI initiatives aimed at
30 ensuring appropriate referral of patients with CKD from PHC to clinical nephrology programs.
31
32 PHC providers are defined as family physicians, family doctors, and general practitioners
33 (including nurse practitioners) in the primary care setting; we will exclude general internists and
34 pediatricians who may be considered PHC providers in certain geographic regions.³⁸ We will
35 also exclude studies that include general internists and/or pediatricians among eligible referral
36 sources. We chose to exclude such studies given that our focus is to assess the impact of
37 implementing QI on referrals from primary care to nephrology. Including studies with referrals
38 from general internal medicine (GIM) and pediatrics could create heterogeneity among the
39 studies and confound our outcome and conclusions given that GIM and pediatrics, in many
40 places, are considered specialists rather than primary care. It is reassuring that this category of
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 referrals from general medicine and pediatrics are small (<10% of all referrals to nephrology)
4
5 based on empirical information available to use, and the referral model within the Canadian
6
7 health system where primary care providers (family physicians and GPs) constitute the main
8
9 gatekeepers to specialist care. The protocol for this study is based on Preferred Reporting Items
10
11 for Systematic reviews and Meta-Analysis for Protocols 2015 (PRISMA-P-2015).³⁹ We will
12
13 follow the PRISMA 2020 methodological guidelines (PRISMA 2020) as we conduct and report
14
15 the findings of our systematic review.⁴⁰ The protocol for this study is registered with
16
17 PROSPERO (CRD42021247756). We have outlined the types of studies to be included based on
18
19 the nature of participants, interventions applied, outcomes reported, and study designs:
20
21
22

- 23
24 - Types of participants. We will include studies with participants over 18 years of age,
25
26 regardless of sex, ethnicity, and geographic location who had been diagnosed with CKD
27
28 but had not initiated KRT when a study intervention was first implemented.
29
30
- 31 - Types of interventions. We will include any initiative or program designed to ensure
32
33 guideline-concordant referrals or to reduce unnecessary referrals of patients with CKD
34
35 from a primary care provider to a nephrology specialist. Various methods have been
36
37 employed previously, including but not limited to: CKD management/referral pathways,
38
39 toolkits, electronic referral systems, structured referral forms, and practice facilitation
40
41 (i.e., consultant-led educational programs for primary care practitioners). We will
42
43 categorize these studies based on the focus of the intervention, as described in previous
44
45 studies:^{32,41} (a) provider education; (b) provider reminder systems; (c) audit and
46
47 feedback; (d) organizational change; (e) financial incentives, regulation, and policy; and
48
49 (f) other. (Table 1).
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 - Types of studies. We will include randomized trials, controlled clinical trials, controlled
4 before-after studies, interrupted time series studies, QI reports, and descriptive studies.
5
6
7
8
9

10 *Search strategy*

11 We have developed a search strategy in consultation with a research librarian (LH) (Appendix
12 1). We will search the following electronic databases— MEDLINE, Embase, Cochrane Library,
13 CINAHL, Web of Science, and PsycINFO —using a combination of controlled vocabulary
14 search terms ; the MEDLINE search strategy is shown in Supplementary Table S1. We also will
15 manually search the references of publications meeting our criteria to identify any other work
16 relevant to our review. Furthermore, we will search grey literature (conference abstracts and
17 proceedings, government and organizational reports, working papers, policy papers) in
18 consultation with a librarian.
19
20
21
22
23
24
25
26
27
28
29
30
31

32 *Study outcomes*

33 Our outcomes of interest are changes to process-based QI measures: wait times, changes in the
34 total number of referrals, and changes in the proportion of guideline-concordant referrals. We
35 anticipate that included studies will have used various guidelines specific to geographic locations
36 and local practice patterns. For studies that do not specify certain guideline referral criteria, we
37 will document that referral criteria were not used.
38
39
40
41
42
43
44
45
46
47
48

49 *Data collection and analysis*

50 The PRISMA flow diagram summarizes the recommended study selection process (Figure 1). To
51 screen and select studies to be included, we will use a two-stage collaborative review process. In
52 the first stage, two reviewers (AG and NS) will independently review titles and abstracts of
53
54
55
56
57
58
59
60

1
2
3 retrieved studies based on the inclusion and exclusion criteria listed in Table 2. In the second
4
5 stage, full texts of the selected studies will be obtained by these reviewers and analyzed
6
7 independently to determine eligibility for inclusion in our final review. For both the first and
8
9 second stages of screening, studies will be included if there is consensus between the two
10
11 reviewers. If there is a disagreement, a third reviewer (IO) will resolve such conflicts and make
12
13 decision on eligibility. For any excluded study, we will record at least one reason for exclusion.
14
15
16
17
18

19 *Data extraction and management*

20
21 Two reviewers will independently retrieve data and enter the summarized details into a data
22
23 extraction form in Microsoft Excel. Data will include type of study, study design, publication
24
25 year, first author, location of study and local healthcare system (e.g. private vs. public), CKD
26
27 stages included in study, assessment of kidney function (eGFR, serum creatinine, and urine
28
29 albumin levels), referral guidelines/criteria used, a description of the QI intervention utilized,
30
31 duration of intervention and follow up, wait times, and changes in total number of referrals and
32
33 the proportion of guideline-concordant referrals.
34
35
36
37
38
39

40 *Assessment of risk of bias in included studies*

41
42 We will adapt and utilize the Cochrane Effective Practice and Organization of Care (EPOC) risk
43
44 of bias criteria⁴² to assess methodological quality and evaluate risk of bias in our retrieved
45
46 studies. The risk of bias per study will be displayed in a risk of bias summary table, and any
47
48 discrepancies will be resolved by a third reviewer.
49
50
51
52
53

54 *Data synthesis and analysis*

1
2
3 We will report changes in wait times, total referrals, and the proportion of guideline-concordant
4 referrals associated with the QI interventions utilized in each study. Changes in the number of
5 referrals, the proportion of guideline-concordant referrals, and other outcomes associated with QI
6 interventions will be presented as absolute values and reported in the same way across all
7 studies. All wait times will be reported as number of days.
8
9

10
11
12
13
14
15
16
17 If concerns arise regarding missing or unclear data in the studies analyzed, we will contact the
18 authors to request information related to study methods, referral criteria used, and changes in
19 guideline-concordant referrals. Missing outcome data will be summarized in the data extraction
20 form and noted in the risk of bias section. Characteristics of included studies will be summarized
21 in tables. Intervention effects will be calculated as relative risks (RRs) with 95% CIs for
22 dichotomous data, and mean differences (MDs) with 95% CIs for continuous variables. If we
23 identify a sufficient number of studies, and clinical and methodological heterogeneity are
24 reasonable, we will perform a meta-analysis to summarize pooled results using a random effects
25 model.⁴³ Statistical heterogeneity will be quantified using I^2 statistics⁴⁴ in each analysis. If
26 heterogeneity between studies is high ($I^2 > 50\%$), then data will be reported descriptively and we
27 will provide a narrative synthesis of included studies using the Synthesis Without Meta-analysis
28 (SWiM) reporting guideline as a framework.⁴⁵ We will assess publication bias using a
29 regression-based test⁴⁶ and by visually inspecting funnel plots.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 We will conduct a stratified meta-analysis by study characteristics. These include: the use of
50 KDIGO guidelines vs. others, CKD stage at referral, and country income group (low and middle
51 income vs. high income). We will perform categorical comparisons of the different types of QI
52
53
54
55
56
57
58
59

1
2
3 interventions (i.e., provider education; provider reminder systems; audit and feedback;
4 organizational change; financial incentives, regulation, and policy; and other).³² We will
5
6 compare the number of QI interventions in each category and the overall impacts of each on wait
7
8 times, referral numbers, and the proportion of guideline-concordant referrals. This information
9
10 will be summarized in table format, similar to previous studies that have examined the impacts of
11
12 QI interventions on referral rates.^{37,38}
13
14
15
16
17
18

19 *Patient and public involvement*

20
21 This protocol for a systematic review will not utilize patient or public involvement. Because no
22
23 patient data will be collected at this step, this study does not require ethics approval. However,
24
25 we hope to form focus groups in the future where we will promote patient engagement by
26
27 soliciting and incorporating the opinions of CKD patients regarding the relevance and
28
29 implications of the study protocol and results. We hope to form similar focus groups with PHC
30
31 providers. We also will involve policy makers at Alberta Health Services who will be interested
32
33 in analyzing QI measures to enhance local health policies and practices. Furthermore, we will
34
35 collaborate with scientific researchers at our institutions and others who are interested in this
36
37 topic and have performed relevant work in this field. These groups will be engaged after the
38
39 protocol is published and the results of the systematic review have been synthesized.
40
41
42
43
44
45

46 *Timeline*

47
48 We will collect data and develop our database from August to December 2021, analyze our data
49
50 and compile our results from January to June 2022, and engage in knowledge translation activities
51
52 from July to December 2022 (Figure 2).
53
54
55
56
57
58
59
60

Ethics and dissemination

Ethics approval will not be needed for our project since we will analyze data from already published studies. Our findings will be shared using traditional approaches, including open access peer-reviewed publication(s), presentations at meetings, and a report.

Discussion

QI initiatives have significant potential to close quality gaps, improve health systems, and enhance patient outcomes. To the best of our knowledge, no systematic reviews have been performed to examine different QI interventions that have been trialed to ensure appropriate referrals of CKD patients from PHC to nephrology. Our analysis will yield a summary of which types of QI interventions improve referral patterns. These results can guide the strategic implementation of future QI initiatives to improve referral patterns and may ultimately enhance knowledge and CKD management practices in primary care settings, improve referral and triage systems, and increase the proportion of guideline-concordant referrals of CKD patients. These implications are significant, especially for public health care systems which may be burdened by both the costs of chronic disease management and long wait times for patients to access specialist care.

Data statement

We will make data available upon reasonable request.

Funding statement

1
2
3 This work is supported by a Canadian Institutes of Health Research (CIHR) Project Scheme
4 Grant (grant number: RES0046966) and AMGEN Canada Incorporated Clinical Innovation
5 Grant (grant number: RES0041633) awarded to AB. The funders played no role in preparing the
6
7
8
9
10 protocol content or in drafting the manuscript.
11
12
13
14
15

16 **Competing interest statement**

17
18
19 None
20
21
22
23
24

25 **Author contributions**

26
27
28 AG, NS, FY, IO, and AB developed the concept and drafted the manuscript. FY produced
29
30 figures for manuscript. LH drafted the search strategy. NS registered the study with PROSPERO.
31
32 LH, AGrill, AS, AA, BB, DC, KJ, MC, NS, PR, SS, SB, SK, SC, SShojai, VD, and AW were
33
34 involved in developing the protocol methods and revising the manuscript. All authors approved
35
36 the final version to be published.
37
38
39
40
41

42 **Acknowledgements**

43
44 The authors thank Ms. Sophanny Tiv for her assistance in producing figures for the manuscript.
45
46
47
48
49

50 **Figures**

51 Figure 1: Study selection process

52
53 Figure 2: Project timeline
54
55
56
57
58
59
60

References

1. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2020;395(10225):709-733. doi:10.1016/S0140-6736(20)30045-3
2. Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. *Lancet*. 2015;385(9981):1975-1982. doi:10.1016/S0140-6736(14)61601-9
3. Grill AK, Brimble S. Approach to the detection and management of chronic kidney disease: *Can Fam Physician*. 2018;64(10):728-735. <http://www.ncbi.nlm.nih.gov/pubmed/30315015>
<http://www.ncbi.nlm.nih.gov/pubmed/30315015>
4. Vassalotti JA, Centor R, Turner BJ, Greer RC, Choi M, Sequist TD. Practical approach to detection and management of chronic kidney disease for the primary care clinician. *Am J Med*. 2016;129(2):153-162.e7. doi:10.1016/j.amjmed.2015.08.025
5. Alberta Health Services. Kidney Health Strategic Clinical Network 2016–2019 transformational roadmap. Published online 2019. <http://www.albertahealthservices.ca/assets/about/scn/ahs-scn-kh-transformational-roadmap.pdf>
6. Bello AK, Ronksley PE, Tangri N, et al. Prevalence and demographics of CKD in Canadian primary care practices: a cross-sectional study. *Kidney Int Reports*. 2019;4(4):561-570. doi:10.1016/j.ekir.2019.01.005

- 1
2
3 7. Manns B, McKenzie SQ, Au F, Gignac PM, Geller LI. The financial impact of advanced
4 kidney disease on Canada Pension Plan and private disability insurance costs. *Can J*
5
6 *Kidney Heal Dis*. 2017;4(1):2054358117703986. doi:10.1177/2054358117703986
7
8
9
- 10
11 8. Smith DH, Gullion CM, Nichols G, Keith DS, Brown JB. Cost of medical care for chronic
12 kidney disease and comorbidity among enrollees in a large HMO population. *J Am Soc*
13 *Nephrol*. 2004;15(5):1300-1306. doi:10.1097/01.ASN.0000125670.64996.BB
14
15
16
17
- 18 9. Wyld MLR, Lee CMY, Zhuo X, et al. Cost to government and society of chronic kidney
19 disease stage 1–5: a national cohort study. *Intern Med J*. 2015;45(7):741-747.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
10. Manns B, Hemmelgarn B, Tonelli M, et al. The cost of care for people with chronic
kidney disease. *Can J Kidney Heal Dis*. 2019;4(6):2054358119835521.
doi:10.1177/2054358119835521
11. Honeycutt AA, Segel JE, Zhuo X, Hoerger TJ, Imai K, Williams D. Medical costs of
CKD in the medicare population. *J Am Soc Nephrol*. 2013;24(9):1478-1483.
doi:10.1681/ASN.2012040392
12. Golestaneh L, Alvarez PJ, Reaven NL, et al. All-cause costs increase exponentially with
increased chronic kidney disease stage. *Am J Manag Care*. 2017;23(10 Suppl):S163-S172.
13. Manns BJ, Mendelssohn DC, Taub KJ. The economics of end-stage renal disease care in
Canada: incentives and impact on delivery of care. *Int J Health Care Finance Econ*.
2007;7(2-3):149-169. doi:10.1007/s10754-007-9022-y
14. Lee H, Manns B, Taub K, et al. Cost analysis of ongoing care of patients with end-stage

- 1
2
3 renal disease: the impact of dialysis modality and dialysis access. *Am J Kidney Dis.*
4
5 2002;40(3):611-622. doi:10.1053/ajkd.2002.34924
6
7
8
9 15. Akbari A, Clase CM, Acott P, et al. Canadian Society of Nephrology commentary on the
10
11 KDIGO clinical practice guideline for CKD evaluation and management. *Am J Kidney*
12
13 *Dis.* 2015;65(2):177-205. doi:10.1053/j.ajkd.2014.10.013
14
15
16 16. KDIGO, CKD. KDIGO CPG for evaluation & management of CKD 2013. *Kidney Int*
17
18 *Suppl.* 2013;3(1):1-150.
19
20
21 17. Brimble KS, Boll P, Grill AK, et al. Impact of the KidneyWise toolkit on chronic kidney
22
23 disease referral practices in Ontario primary care: a prospective evaluation. *BMJ Open.*
24
25 2020;10(2):e032838. doi:10.1136/bmjopen-2019-032838
26
27
28
29 18. CKD pathway. Accessed June 12, 2021. <http://www.ckdpathway.ca/>
30
31
32 19. De Coster C, McLaughlin K, Noseworthy TW. Criteria for referring patients with renal
33
34 disease for nephrology consultation: a review of the literature. *J Nephrol.* 2010;23(4):399-
35
36 407.
37
38
39 20. Hommel K, Madsen M, Kamper AL. The importance of early referral for the treatment of
40
41 chronic kidney disease: a Danish nationwide cohort study. *BMC Nephrol.* 2012;13:108.
42
43 doi:10.1186/1471-2369-13-108
44
45
46
47 21. Smart NA, Dieberg G, Ladhani M, Titus T. Early referral to specialist nephrology services
48
49 for preventing the progression to end-stage kidney disease. *Cochrane Database Syst Rev.*
50
51 2014;6:CD007333. doi:10.1002/14651858.CD007333.pub2
52
53
54
55 22. Navaneethan SD, Aloudat S, Singh S. A systematic review of patient and health system
56
57
58
59
60

- characteristics associated with late referral in chronic kidney disease. *BMC Nephrol.* 2008;9:3. doi:10.1186/1471-2369-9-3
23. Stack AG. Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the United States. *Am J Kidney Dis.* 2003;41(2):301-318. doi:10.1053/ajkd.2003.50038
24. Kazmi WH, Obrador GT, Khan SS, Pereira BJJ, Kausz AT. Late nephrology referral and mortality among patients with end-stage renal disease: a propensity score analysis. *Nephrol Dial Transplant.* 2004;19(7):1808-1814. doi:10.1093/ndt/gfg573
25. MacKinnon JC. Wait times in Canada. *Healthc Manag Forum.* 2017;30(4):190-192. doi:10.1177/0840470417700162
26. Wright J, Glenister KM, Thwaites R, Terry D. The importance of adequate referrals for chronic kidney disease. *Aust J Gen Pract.* 2018;47(1-2):58-62. doi:10.31128/AFP-08-17-4302
27. Lane C, Pirabhahar S, Robins J, Tranter S, Brown M, Katz I. Improving nephrology service delivery—accessing the specialist. *Aust Fam Physician.* 2016;45(4):223-228.
28. Bello AK, Ronksley PE, Tangri N, et al. Quality of chronic kidney disease management in Canadian primary care. *JAMA Netw open.* 2019;2(9):e1910704. doi:10.1001/jamanetworkopen.2019.10704
29. Patwardhan MB, Samsa GP, Matchar DB, Haley WE. Advanced chronic kidney disease practice patterns among nephrologists and non-nephrologists: a database analysis. *Clin J Am Soc Nephrol.* 2007;2(2):277-283. doi:10.2215/CJN.02600706

- 1
2
3 30. Østbye T, Yarnall KSH, Krause KM, Pollak KI, Gradison M, Michener JL. Is there time
4 for management of patients with chronic diseases in primary care? *Ann Fam Med*.
5
6 2005;3(3):209-214. doi:10.1370/afm.310
7
8
9
10
11 31. Yarnall KSH, Pollak KI, Østbye T, Krause KM, Michener JL. Primary care: is there
12 enough time for prevention? *Am J Public Health*. 2003;93(4):635-641.
13
14 doi:10.2105/AJPH.93.4.635
15
16
17
18 32. Shojania K, McDonald K, Watcher R, Owens D. *Closing the quality gap: a critical*
19 *analysis of quality improvement strategies. Volume 1: series overview and methodology.*
20 *Technical Review 9*; 2004.
21
22
23
24
25
26 33. Stone EG, Morton SC, Hulscher ME, et al. Interventions that increase use of adult
27 immunization and cancer screening services: A meta-analysis. *Ann Intern Med*.
28 2002;136(9):641-651. doi:10.7326/0003-4819-136-9-200205070-00006
29
30
31
32
33 34. Stafford RS. Alternative strategies for controlling rising cesarean section rates. *JAMA*.
34 1990;263(5):683-687. doi:10.1001/jama.1990.03440050077037
35
36
37
38 35. Weingarten SR, Henning JM, Badamgarav E, et al. Interventions used in disease
39 management programmes for patients with chronic illness which ones work? Meta-
40 analysis of published reports. *BMJ*. 2002;325:925. doi:10.1136/bmj.325.7370.925
41
42
43
44
45
46 36. Grimshaw JM, Shirran L, Thomas R, et al. Changing provider behavior: an overview of
47 systematic reviews of interventions. *Med Care*. 2001;39(8 Suppl 2):II2-45.
48
49
50
51 37. Faulkner A, Mills N, Bainton D, et al. A systematic review of the effect of primary care-
52 based service innovations on quality and patterns of referral to specialist secondary care.
53
54
55
56
57
58
59

- 1
2
3 *Br J Gen Pract.* 2003;53:878-884.
4
5 <http://www.ingentaconnect.com/content/rcgp/bjgp/2003/00000053/00000496/art00011%5>
6
7 [Cnhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC1314732/pdf/14702909.pdf](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1314732/pdf/14702909.pdf)
8
9
10
11 38. Akbari A, Mayhew A, Al-Alawi MA, et al. Interventions to improve outpatient referrals
12 from primary care to secondary care. *Cochrane Database Syst Rev.* 2008;4:CD005471.
13 doi:10.1002/14651858.CD005471.pub2
14
15
16
17
18 39. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review
19 and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev.* 2015;4(1):1.
20 doi:10.1186/2046-4053-4-1
21
22
23
24
25
26 40. Page MJ, McKenzie JE, Bossuyt PM, et al. Updating guidance for reporting systematic
27 reviews: development of the PRISMA 2020 statement. *J Clin Epidemiol.* 2021;134:103-
28 112. doi:10.1016/j.jclinepi.2021.02.003
29
30
31
32
33 41. McDonald KM, Chang C, Schultz EJ. *Methods research report. Through the quality*
34 *kaleidoscope: reflections on the science and practice of improving health care quality;*
35 2013. Accessed June 13, 2021. www.EffectiveHealthCare.ahrq.gov/reports/final.cfm.
36
37
38
39
40
41 42. Cochrane Effective Practice and Organisation of Care (EPOC). *Suggested risk of bias*
42 *criteria for EPOC reviews.* 2017;1-4.
43 [https://epoc.cochrane.org/sites/epoc.cochrane.org/files/public/uploads/Resources-for-](https://epoc.cochrane.org/sites/epoc.cochrane.org/files/public/uploads/Resources-for-authors2017/suggested_risk_of_bias_criteria_for_epoc_reviews.pdf)
44 [authors2017/suggested_risk_of_bias_criteria_for_epoc_reviews.pdf](https://epoc.cochrane.org/sites/epoc.cochrane.org/files/public/uploads/Resources-for-authors2017/suggested_risk_of_bias_criteria_for_epoc_reviews.pdf)
45
46
47
48
49
50
51 43. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials.*
52 1986;7(3):177-188. doi:10.1016/0197-2456(86)90046-2
53
54
55
56
57
58
59
60


- 1
2
3 44. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*.
4 2002;21(11):1539-1558. doi:10.1002/sim.1186
5
6
7
8 45. Campbell M, Mckenzie JE, Sowden A, et al. Synthesis without meta-analysis (SWiM) in
9 systematic reviews: reporting guideline. *BMJ*. 2020;368:16890. doi:10.1136/bmj.l6890
10
11
12
13 46. Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ. Publication and related biases.
14 *Health Technol Assess*. 2000;4(10). doi:10.3310/hta4100
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Taxonomy of interventions used in the systematic review

Intervention type	Definition
Provider education	Interventions aimed at training care providers, including educational workshops/meetings, outreach programs, and distribution of educational materials
Provider reminder systems	Providing specific information about clinical encounters with the aim of prompting clinicians to recall information or promote a certain aspect of care
Audit and feedback	Methods that provide a review of clinical performance for health care providers and institutions to help improve quality of a certain aspect of care
Other	Interventions not covered in the previously listed items, e.g. organizational change initiatives, financial incentives, patient reminder systems, patient education, promotion of self-management, and facilitated relay of clinical data to providers


Table 2: Inclusion and exclusion criteria for this study

Inclusion criteria	Exclusion criteria
- Studies involving CKD patients who are not being managed with KRT.	- Studies where referrals are not from PHC to nephrology (e.g. referrals from or to general internal medicine for CKD).
- Studies reporting changes in process-based QI measures (wait times, number of referrals, or changes in guideline-concordant referrals) for CKD patients.	- Review articles, editorials, letters to the editor, commentaries, case studies, case reports, images.
- Studies reporting at least one outcome measure (referral numbers, rate or proportion of guideline concordant referrals, or wait times).	- Studies where we cannot obtain relevant data (e.g., method of intervention or outcomes reported) even after contacting authors.
- No restrictions on publication date.	- Studies where the outcomes of interest (referral numbers, wait times, guideline-concordant referral rate) are not clearly reported.
- No restrictions on language.	
- No restrictions on the referral guidelines (e.g. KDIGO vs. local/national guidelines) used.	



*other sources (online publications, technical reports, policy briefs, etc.)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47



Supplementary Table S1: Medical Subject Headings for MEDLINE database search

1. exp Renal Insufficiency, Chronic/
2. Chronic Kidney disease*.mp.
3. chronic kidney insufficienc*.mp.
4. chronic renal disease*.mp.
5. chronic renal insufficienc*.mp.
6. CKD.mp.
7. Renal fail*.mp.
8. Kidney fail*.mp.
9. or/1-8
10. Organizational innovation/
11. clinical audit/ or medical audit/ or nursing audit/
12. Quality Improvement/
13. education/ or education, professional/ or education, continuing/ or education, medical, continuing/ or education, nursing, continuing/ or education, professional, retraining/
14. (Quality* adj2 improv*).mp.
15. ((Provider or doctor* or physician* or nurse* or health personnel* or healthcare personnel*) adj4 (educat* or learn* or "reminder system*")).mp.
16. (Organization* adj3 (change* or restructure* or revamp or reform* or revise* or innovat*)).mp.
17. Audit*.mp.
18. Feedback/
19. feedback.mp.
20. Physician Incentive Plans/
21. (financ* adj2 incentiv*).mp.
22. (incent* adj2 (plan or plans)).mp.
23. social control, formal/ or government regulation/ or mandatory programs/ or social control policies/ or organizational policy/ or public policy/ or health policy/ or health care reform/
24. regulat*.mp.
25. (policy or policies).mp.
26. or/10-25
27. "Referral and Consultation"/ or (referral* or consultation* or consults or consult).mp.
28. 26 and 27
29. (((Improv* or amerlior* or better or enhance* or correct* or increase* or progress or facilitat* or promote* or raise* or augment* or elevate* or appropriate) adj3 (referral* or consultation* or consult or consults)) and (guide* or policy or policies or regulation* or toolkit* or report*)).mp.
30. ((Reduce or reduction* or decrease* or lessen* or minimize* or diminish* or lower* or avoid*) adj3 ((unnecessary or avoidable or superfluous or unneeded or irrelevant or late or traditional) adj2 (referral* or consultation* or consult or consults))).mp.
31. wait* time*.mp. and ((referral* or consultation* or consult or consults).mp. or "Referral and Consultation"/) and (guide* or policy or policies or regulation* or toolkit* or reporting).mp.
32. 28 or 29 or 30 or 31
33. 9 and 32

Appendix: Search strategies for all databases in protocol

All searches were conducted with no additional filters or limits.

Medline – 431 results

Ovid MEDLINE(R) ALL

1. exp Renal Insufficiency, Chronic/
2. Chronic Kidney disease*.mp.
3. chronic kidney insufficienc*.mp.
4. chronic renal disease*.mp.
5. chronic renal insufficienc*.mp.
6. CKD.mp.
7. Renal fail*.mp.
8. 12.mp.
9. or/1-8
10. Organizational innovation/
11. clinical audit/ or medical audit/ or nursing audit/
12. Quality Improvement/
13. education/ or education, professional/ or education, continuing/ or education, medical, continuing/ or education, nursing, continuing/ or education, professional, retraining/
14. (Quality adj2 improv*).mp.
15. ((Provider or doctor* or physician* or nurse* or health personnel* or healthcare personnel*) adj4 (educat* or learn* or "reminder system*")).mp.
16. (Organization* adj3 (change* or restructure* or revamp* or reform* or revise* or innovat*)).mp.
17. Audit*.mp.
18. Feedback/
19. [feedback.mp.](#)
20. Physician Incentive Plans/
21. (financ* adj2 incentiv*).mp.
22. (incent* adj2 (plan or plans)).mp.
23. social control, formal/ or government regulation/ or mandatory programs/ or social control policies/ or organizational policy/ or public policy/ or health policy/ or health care reform/
24. regulat*.mp.
25. (policy or policies).mp.
26. or/10-25
27. "Referral and Consultation"/ or (referral* or consultation* or consults or consult).mp.
28. 26 and 27
29. (((Improv* or amerlior* or better* or enhance* or correct* or increase* or progress* or facilitat* or promote* or raise* or augment* or elevate* or appropriate) adj3 (referral* or consultation* or consult or consults)) and (guide* or policy or policies or regulation* or toolkit* or report*)).mp.
30. ((Reduc* or decrease* or lessen* or minimize* or diminish* or lower* or avoid*) adj3 ((unnecessary or avoidable or superfluous or unneeded or irrelevant or late or traditional) adj2 (referral* or consultation* or consult or consults))).mp.
31. wait* time*.mp. and ((referral* or consultation* or consult or consults).mp. or "Referral and Consultation"/) and (guide* or policy or policies or regulation* or toolkit* or reporting).mp.

32. 28 or 29 or 30 or 31

33. 9 and 32

Embase – 1322 results

Ovid platform

1. exp chronic kidney failure/
2. Chronic Kidney disease*.mp.
3. chronic kidney insufficienc*.mp.
4. chronic renal disease*.mp.
5. chronic renal insufficienc*.mp.
6. CKD.mp.
7. Renal fail*.mp.
8. Kidney fail*.mp.
9. or/1-8
10. clinical audit/ or nursing audit/
11. total quality management/
12. education/ or adult education/ or continuing education/ or vocational education/
13. (Quality adj2 improv*).mp.
14. ((Provider* or doctor* or physician* or nurse* or health personnel* or healthcare personnel*) adj4 (educat* or learn* or "reminder system*")).mp.
15. (Organization* adj3 (change* or restructure* or revamp* or reform* or revise* or innovat*)).mp.
16. Audit*.mp.
17. feedback.mp.
18. (financ* adj2 incentiv*).mp.
19. (incent* adj2 (plan or plans)).mp.
20. social control/ or government regulation/ or mandatory program/ or organizational policy/ or public policy/ or health care policy/
21. regulat*.mp.
22. (policy or policies).mp.
23. or/10-22
24. exp consultation/ or patient referral/ or (referral* or consultation* or consults or consult).mp.
25. 23 and 24
26. (((Improv* or amerlior* or better* or enhance* or correct* or increase* or progress* or facilitat* or promote* or raise* or augment* or elevate* or appropriate) adj3 (referral* or consultation* or consult or consults)) and (guide* or policy or policies or regulation* or toolkit* or report*)).mp.
27. ((Reduce* or decrease* or lessen* or minimize* or diminish* or lower* or avoid*) adj3 ((unnecessary or avoidable or superfluous or unneeded or irrelevant or late or traditional) adj2 (referral* or consultation* or consult or consults))).mp.
28. wait* time*.mp. and ((referral* or consultation* or consult or consults).mp. or exp consultation/ or patient referral/) and (guide* or policy or policies or regulation* or toolkit* or reporting).mp.
29. 25 or 26 or 27 or 28
30. 9 and 29

PsycINFO – 15 results

APA PsycInfo, Ovid platform

1. kidney diseases/

- 1
- 2
- 3 2. Chronic Kidney disease*.mp.
- 4 3. chronic kidney insufficienc*.mp.
- 5 4. chronic renal disease*.mp.
- 6 5. chronic renal insufficienc*.mp.
- 7 6. CKD.mp.
- 8 7. Renal fail*.mp.
- 9 8. Kidney fail*.mp.
- 10 9. or/1-8
- 11 10. clinical audits/
- 12 11. education/
- 13 12. (Quality adj2 improv*).mp.
- 14 13. ((Provider or doctor* or physician* or nurse* or health personnel* or healthcare personnel*) adj4
- 15 (educat* or learn* or "reminder system*")).mp.
- 16 14. (Organization* adj3 (change* or restructure* or revamp* or reform* or revise* or innovat*)).mp.
- 17 15. Audit*.mp.
- 18 16. feedback.mp.
- 19 17. (financ* adj2 incentiv*).mp.
- 20 18. (incent* adj2 (plan or plans)).mp.
- 21 19. monetary incentives/
- 22 20. policy making/ or government policy making/ or health care policy/ or social control/ or health care
- 23 reform/
- 24 21. regulat*.mp.
- 25 22. (policy or policies).mp.
- 26 23. or/10-22
- 27 24. professional consultation/ or professional referral/ or (referral* or consultation* or consults or
- 28 consult).mp.
- 29 25. 23 and 24
- 30 26. (((Improv* or amerlior* or better* or enhance* or correct* or increase* or progress* or facilitat* or
- 31 promote* or raise* or augment* or elevate* or appropriate) adj3 (referral* or consultation* or consult
- 32 or consults)) and (guide* or policy or policies or regulation* or toolkit* or report*)).mp.
- 33 27. ((Reduce* or decrease* or lessen* or minimize* or diminish* or lower* or avoid*) adj3 ((unnecessary
- 34 or avoidable or superfluous or unneeded or irrelevant or late or traditional) adj2 (referral* or
- 35 consultation* or consult or consults))).mp.
- 36 28. wait* time*.mp. and ((referral* or consultation* or consult or consults).mp. or professional
- 37 consultation/ or professional referral/) and (guide* or policy or policies or regulation* or toolkit* or
- 38 reporting).mp.
- 39 29. 25 or 26 or 27 or 28
- 40 30. 9 and 29

47 Cochrane – 314 results

48 Cochrane Central

- 49
- 50 #1 MeSH descriptor: [Renal Insufficiency, Chronic] explode all trees
- 51 #2 "Chronic Kidney" NEXT disease*
- 52 #3 "chronic kidney" NEXT insufficienc*
- 53 #4 "chronic renal" NEXT disease*
- 54 #5 "chronic renal" NEXT insufficienc*
- 55 #6 CKD
- 56
- 57
- 58
- 59
- 60

- 1
2
3 #7 Renal NEXT fail*
4 #8 Kidney NEXT fail*
5 #9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
6 #10 MeSH descriptor: [Organizational Innovation] this term only
7 #11 MeSH descriptor: [Clinical Audit] this term only
8 #12 MeSH descriptor: [Medical Audit] this term only
9 #13 MeSH descriptor: [Nursing Audit] this term only
10 #14 MeSH descriptor: [Quality Improvement] this term only
11 #15 MeSH descriptor: [Education] this term only
12 #16 MeSH descriptor: [Education, Professional] in all MeSH products
13 #17 MeSH descriptor: [Education, Continuing] this term only
14 #18 MeSH descriptor: [Education, Medical, Continuing] this term only
15 #19 MeSH descriptor: [Education, Nursing, Continuing] this term only
16 #20 MeSH descriptor: [Education, Professional, Retraining] this term only
17 #21 Quality NEXT improv*
18 #22 (Provider OR doctor* OR physician* OR nurse* OR (health NEXT personnel*) OR (healthcare
19 NEXT personnel*)) NEAR/4 (educat* OR learn* OR (reminder NEXT system*))
20 #23 Organization* NEAR/3 (change* OR restructure* OR revamp* OR reform* OR revise* OR
21 innovat*)
22 #24 audit*
23 #25 MeSH descriptor: [Feedback] this term only
24 #26 Feedback
25 #27 MeSH descriptor: [Physician Incentive Plans] this term only
26 #28 financ* NEAR/2 incentiv*
27 #29 incent* NEAR/2 (plan OR plans)
28 #30 MeSH descriptor: [Social Control, Formal] this term only
29 #31 MeSH descriptor: [Government Regulation] this term only
30 #32 MeSH descriptor: [Mandatory Programs] this term only
31 #33 MeSH descriptor: [Social Control Policies] this term only
32 #34 MeSH descriptor: [Organizational Policy] this term only
33 #35 MeSH descriptor: [Public Policy] this term only
34 #36 MeSH descriptor: [Health Policy] this term only
35 #37 MeSH descriptor: [Health Care Reform] this term only
36 #38 regulat*
37 #39 policy OR policies
38 #40 {OR #10-#39}
39 #41 MeSH descriptor: [Referral and Consultation] this term only
40 #42 referral* OR consultation* OR consults OR consult
41 #43 #41 OR #42
42 #44 #40 AND #43
43 #45 ((Improv* OR amerlior* OR better* OR enhance* OR correct* OR increase* OR progress* OR
44 facilitat* OR promote* OR raise* OR augment* OR elevate* OR appropriate) NEAR/3 (referral*
45 OR consultation* OR consult OR consults)) AND (guide* OR policy OR policies OR regulation* OR
46 toolkit* OR report*)
47 #46 ((Reduc* OR decrease* OR lessen* OR minimize* OR diminish* OR lower* OR avoid*) NEAR/3
48 ((unnecessary OR avoidable OR superfluous OR unneeded OR irrelevant OR late OR traditional)
49 NEAR/2 (referral* OR consultation* OR consult OR consults)))
50
51
52
53
54
55
56
57
58
59
60

1
2
3 #47 (wait* NEXT time*) AND (#43 AND (guide* OR policy OR policies OR regulation* OR toolkit* OR
4 reporting))
5 #48 {OR #44-#47}
6 #49 #9 AND #48
7

8
9 314 results

10
11
12 **CINAHL – 251 results**

13 CINAHL Plus with Full Text, EBSCO platform

14
15 S1 (MH "Kidney Failure, Chronic")
16 S2 "Chronic Kidney disease*"
17 S3 "chronic kidney insufficienc*"
18 S4 "chronic renal disease*"
19 S5 "chronic renal insufficienc*"
20 S6 CKD
21 S7 "Renal fail*"
22 S8 "Kidney fail*"
23
24 S9 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8
25 S10 (MH "Nursing Audit") OR (MH "Audit")
26 S11 (MH "Quality Improvement")
27 S12 (MH "Education")
28 S13 (MH "Refresher Courses")
29 S14 (MH "Education, Continuing+") OR (MH "Education, Medical, Continuing") OR (MH "Education,
30 Nursing, Continuing") OR (MH "Education, Continuing (Credit)")
31 S15 Quality N2 improv*
32 S16 (Provider OR doctor* OR physician* OR nurse* OR "health personnel*" OR "healthcare
33 personnel*") N4 (educat* OR learn* OR "reminder system*")
34 S17 Organization* N3 (change* OR restructure* OR revamp* OR reform* OR revise* OR innovat*)
35 S18 Audit*
36 S19 (MH "Feedback")
37 S20 Feedback
38 S21 (MH "Physician Incentive Plans")
39 S22 financ* N2 incentiv*
40 S23 incent* N2 (plan OR plans)
41 S24 (MH "Social Control") OR (MH "Public Policy") OR (MH "Health Policy")
42 S25 (MH "Government Regulations")
43 S26 (MH "Organizational Policies") OR (MH "Hospital Policies")
44 S27 (MH "Health Care Reform")
45 S28 regulat*
46 S29 (policy OR policies)
47 S30 S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22
48 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29
49 S31 (MH "Referral and Consultation")
50 S32 referral* OR consultation* OR consults OR consult
51 S33 S31 OR S32
52 S34 S30 AND S33
53
54
55
56
57
58
59
60

1
2
3 S35 (((Improv* OR amerlior* OR better* OR enhance* OR correct* OR increase* OR progress* OR
4 6facilitate* OR promote* OR raise* OR augment* OR elevate* OR appropriate) N3 (referral* OR
5 consultation* OR consult OR consults)) AND (guide* OR policy OR policies OR regulation* OR
6 toolkit* OR report*))
7
8 S36 ((Reduc* OR decrease* OR lessen* OR minimize* OR diminish* OR lower* OR avoid*) N3
9 ((unnecessary OR avoidable OR superfluous OR unneeded OR irrelevant OR late OR traditional)
10 N2 (referral* OR consultation* OR consult OR consults)))
11 S37 "wait* time*" AND (S33 AND (guide* OR policy OR policies OR regulation* OR toolkit* OR
12 reporting))
13 S38 S34 OR S35 OR S36 OR S37
14 S39 S9 AND S38
15

16
17
18 **WoS – 589 results**

19 Web of Science – All databases
20
21

- 22 1. TS=("Chronic Kidney disease*" OR "chronic kidney insufficienc*" OR "chronic renal disease*" OR
23 "chronic renal insufficienc*" OR "CKD" OR "Renal fail*" OR "Kidney fail*")
- 24 2. TS((((Quality NEAR/2 improv*) OR ((Provider OR doctor* OR physician* OR nurse* OR "health
25 personnel*" OR "healthcare personnel*") NEAR/4 (educat* OR learn* OR "reminder system*"))
26 OR (Organization* NEAR/3 (change* OR restructure* OR revamp* OR reform* OR revise* OR
27 innovat*)) OR Audit* OR Feedback OR (financ* NEAR/2 incentiv*) OR (incent* NEAR/2 (plan OR
28 plans)) OR regulat* OR policy OR policies) AND (referral* OR consultation* OR consults OR
29 consult)))
30
- 31 3. TS(("wait* time*" AND (referral* OR consultation* OR consults OR consult) AND
32 (guide* OR policy OR policies OR regulation* OR toolkit* OR reporting)))
- 33 4. TS((((Improv* OR amerlior* OR better* OR enhance* OR correct* OR increase* OR progress*
34 OR facilitat* OR promote* OR raise* OR augment* OR elevate* OR appropriate) NEAR/3
35 (referral* OR consultation* OR consult OR consults)) AND (guide* OR policy OR policies OR
36 regulation* OR toolkit* OR report*))
- 37 5. TS(((Reduc* OR decrease* OR lessen* OR minimize* OR diminish* OR lower* OR avoid*)
38 NEAR/3 ((unnecessary OR avoidable OR superfluous OR unneeded OR irrelevant OR late OR
39 traditional) NEAR/2 (referral* OR consultation* OR consult OR consults))))
- 40 6. #2 OR #3 OR #4 OR #5
- 41 7. #1 AND #6
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reporting checklist for protocol of a systematic review and meta analysis.

Based on the PRISMA-P guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Reporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

			Page Number
Title			
Identification	#1a	Identify the report as a protocol of a systematic review	1
Update	#1b	If the protocol is for an update of a previous systematic review, identify as such	N/A

1	Registration		
2			
3			
4		#2	2
5		If registered, provide the name of the registry (such as	
6		PROSPERO) and registration number	
7			
8			
9			
10	Authors		
11			
12			
13	Contact	#3a	1
14		Provide name, institutional affiliation, e-mail address of all	
15		protocol authors; provide physical mailing address of	
16		corresponding author	
17			
18			
19			
20	Contribution	#3b	14
21		Describe contributions of protocol authors and identify the	
22		guarantor of the review	
23			
24			
25			
26	Amendments		
27			
28			
29		#4	N/A
30		If the protocol represents an amendment of a previously	
31		completed or published protocol, identify as such and list	
32		changes; otherwise, state plan for documenting important	
33		protocol amendments	
34			
35			
36			
37			
38			
39	Support		
40			
41			
42	Sources	#5a	14
43		Indicate sources of financial or other support for the review	
44			
45	Sponsor	#5b	14
46		Provide name for the review funder and / or sponsor	
47			
48	Role of sponsor or	#5c	14
49	funder	Describe roles of funder(s), sponsor(s), and / or	
50		institution(s), if any, in developing the protocol	
51			
52			
53	Introduction		
54			
55			
56			
57			
58			
59			
60			

1	Rationale	#6	Describe the rationale for the review in the context of what is	3-8
2			already known	
3				
4				
5				
6	Objectives	#7	Provide an explicit statement of the question(s) the review	8
7			will address with reference to participants, interventions,	
8			comparators, and outcomes (PICO)	
9				
10				
11				
12				
13				
14	Methods			
15				
16				
17	Eligibility criteria	#8	Specify the study characteristics (such as PICO, study	8-9, 23
18			design, setting, time frame) and report characteristics (such	
19			as years considered, language, publication status) to be	
20			used as criteria for eligibility for the review	
21				
22				
23				
24				
25				
26				
27	Information	#9	Describe all intended information sources (such as	8-9
28			electronic databases, contact with study authors, trial	
29	sources		registers or other grey literature sources) with planned dates	
30			of coverage	
31				
32				
33				
34				
35				
36				
37	Search strategy	#10	Present draft of search strategy to be used for at least one	9-10, 25
38			electronic database, including planned limits, such that it	
39			could be repeated	
40				
41				
42				
43				
44				
45	Study records -	#11a	Describe the mechanism(s) that will be used to manage	10
46	data management		records and data throughout the review	
47				
48				
49				
50	Study records -	#11b	State the process that will be used for selecting studies	10
51	selection process		(such as two independent reviewers) through each phase of	
52			the review (that is, screening, eligibility and inclusion in	
53			meta-analysis)	
54				
55				
56				
57				
58				
59				
60				

1	Study records -	#11c	Describe planned method of extracting data from reports	10
2				
3	data collection		(such as piloting forms, done independently, in duplicate),	
4				
5	process		any processes for obtaining and confirming data from	
6				
7			investigators	
8				
9				
10				
11	Data items	#12	List and define all variables for which data will be sought	9
12				
13			(such as PICO items, funding sources), any pre-planned	
14				
15			data assumptions and simplifications	
16				
17				
18	Outcomes and	#13	List and define all outcomes for which data will be sought,	10
19				
20	prioritization		including prioritization of main and additional outcomes, with	
21				
22			rationale	
23				
24				
25				
26	Risk of bias in	#14	Describe anticipated methods for assessing risk of bias of	11
27				
28	individual studies		individual studies, including whether this will be done at the	
29				
30			outcome or study level, or both; state how this information	
31				
32			will be used in data synthesis	
33				
34				
35				
36	Data synthesis	#15a	Describe criteria under which study data will be	11
37				
38			quantitatively synthesised	
39				
40				
41	Data synthesis	#15b	If data are appropriate for quantitative synthesis, describe	11
42				
43			planned summary measures, methods of handling data and	
44				
45			methods of combining data from studies, including any	
46				
47			planned exploration of consistency (such as I ² , Kendall's τ)	
48				
49				
50				
51	Data synthesis	#15c	Describe any proposed additional analyses (such as	11
52				
53			sensitivity or subgroup analyses, meta-regression)	
54				
55				
56				
57				
58				
59				
60				

1	Data synthesis	#15d	If quantitative synthesis is not appropriate, describe the type	N/A
2			of summary planned	
3				
4				
5				
6	Meta-bias(es)	#16	Specify any planned assessment of meta-bias(es) (such as	11
7			publication bias across studies, selective reporting within	
8			studies)	
9				
10				
11				
12				
13				
14	Confidence in	#17	Describe how the strength of the body of evidence will be	N/A
15	cumulative		assessed (such as GRADE)	
16				
17	evidence			
18				
19				
20				
21				

22 The PRISMA-P elaboration and explanation paper is distributed under the terms of the Creative
 23 Commons Attribution License CC-BY. This checklist was completed on 28. June 2021 using
 24 <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with
 25 [Penelope.ai](#)
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60